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We designed a study to provide reversibility and comparative
injury data for several candidate urinary biomarkers of kidney
injury in the United States Food and Drug Administration
biomarker qualification process. The nephrotoxin gentamicin
was given to rats once on each of three days and the animals
were killed during dosing or over the following 42 days.
Between days one and three, all biomarkers except albumin
were elevated, peaked at day 7, and returned to control
levels by day 10 (l- and a-glutathione S-transferases, and
renal papillary antigen-1) or day 15 (kidney injury molecule-1,
lipocalin-2, osteopontin, and clusterin). All biomarkers
performed better during injury than during recovery except
osteopontin, which performed equally well in both time
periods. During the evolution of injury, kidney injury
molecule-1, renal papillary antigen-1, and clusterin best
mirrored the histopathologic lesions. During injury
resolution, kidney injury molecule-1, osteopontin, and blood
urea nitrogen best reflected recovery. Based on
histopathology, necrosis, or apoptosis scoring, kidney injury
molecule-1 was the best biomarker of overall renal injury.
Evaluation by regeneration score showed that renal papillary
antigen-1 best reflected tubular and/or collecting duct
regeneration, especially during recovery. Thus, these
biomarkers performed with different effectiveness when
evaluated by individual pathological processes such as
necrosis, apoptosis, and regeneration.
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In recent years, numerous molecules have been described and
investigated as candidate biomarkers of kidney injury. The
United States Food and Drug Administration (FDA) has
taken an active role in developing a process for qualification
of biomarkers1,2 that would potentially improve the drug
development and regulatory review process. The first FDA
review of biomarker qualification data involved biomarkers
of renal injury and resulted in qualification of seven
biomarkers as supplemental data for evaluation of nephro-
toxicity in nonclinical safety studies.3 More recently, a second
submission has been reviewed with two additional biomar-
kers being recommended for qualification. However, in both
reviews, the biomarker qualification review team felt that
more data were needed before these or any other biomarkers
could be qualified for use in clinical studies. These additional
data would include: biomarker response to a wider array of
nephrotoxic and non-nephrotoxic drugs; refinement of early
detection techniques and definitions; and demonstrated
reversibility following drug cessation.
This study was designed to provide reversibility data as
well as comparative injury responses for eight qualified or
candidate biomarkers of kidney injury using assays commer-
cially available on the Meso Scale Discovery platform. During
evaluation of study data, the four major characteristics of a
good predictive biomarker were evaluated; namely, that (1)
biomarker changes occur before or in concert with lesion
development, (2) biomarker changes are strongly correlated
with lesion development, (3) there is a close relationship
between the amount of observable injury and the amount of
detectable biomarker, and (4) biomarker concentrations
decrease with diminishing injury.3 A well-described nephro-
toxin, gentamicin, was used to create primarily proximal
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tubular injury for comparison of biomarker profiles during
injury evolution and subsequent recovery. In most cases, the
cellular sources and phenotypes during gentamicin-induced
acute kidney injury have been previously described for the
biomarkers evaluated in this study (Table 1).
RESULTS
Figure 1 illustrates the timeline of treatments and killings
throughout this study. No treatment-related morbidity was
observed in experimental animals. One animal died per
acutely following injection (150mg/kg, day 44), two animals
were recruited as sentinels (control, days 36 and 44), and data
from three animals were eliminated because of nontreat-
ment-related issues (control, day 2; 300mg/kg, day 2; and
300mg/kg, day 7). Supplementary Figure S1 online reflects
weight gain from day 0 by treatment group.
Serum analyses revealed no treatment group differences
for albumin (Alb), total protein, alkaline phosphatase,
alanine aminotransferase, amylase, total bilirubin, calcium,
phosphorus, glucose, sodium, potassium, and globulin (data
not shown). Table 2 contains group means of the urinary
proteins, kidney injury molecule-1 (Kim-1), Alb, lipocalin-2
(Lcn-2), clusterin (Clu), osteopontin (Opn), m- and
a-glutathione S-transferases (mGst and aGst), and renal
papillary antigen-1 (Rpa-1) at each time point. The low-dose
group (75mg/kg) demonstrated a time response trend in
each biomarker except for Alb (Figure 2), but at no point
was a statistical difference described between low-dose and
control groups (Table 2). With all biomarkers except Alb,
medium-dose (150mg/kg) and high-dose (300mg/kg)
groups exhibited temporal trends similar to the low-dose
group but with greater magnitude and statistical differences
(Table 2 and Figure 1).
Although Lcn-2, Clu, and Opn demonstrated an elevated
trend, only Kim-1 had significant elevation after a single
treatment (day 1). At that time, significant increases were
seen in both the medium- and high-dose groups. Excluding
Alb, increasing trends continued with minimal exception in
all biomarkers at day 2, or 24 h following a second treatment.
These trends persisted at day 3, or 24 h following a third
treatment, with the high-dose group demonstrating signifi-
cant increases in Kim-1, Lcn-2, and Clu. At day 7 (5 days
following a third and final treatment), all biomarkers had
peaked in all dose groups. With the exception of Alb, all
urinary biomarkers were significantly elevated in the high-
dose group at day 7. Kim-1 was also significantly increased
in the medium-dose group at day 7. Significant increases
in Kim-1, Lcn-2, Clu, and Opn were demonstrated in the
Table 1 | Biomarker cell source and cell phenotype during gentamicin-induced kidney injury
Biomarker Source during injury Source phenotype
Previous gentamicin injury/
localization literature
Alb Synthesized in the liver and
circulates in systemic blood vessels
Dysfunction of glomerular filtration rate
and proximal tubular epithelial re-absorption
Coimbra and Lachat (1988);
Gekle (1998)
Lcn-2 Proximal tubular epithelium Increased in cytoplasm of intact injured cells Devarajan (2008); Sieber et al. (2009);
Zhang et al. (2009)
Clu Proximal tubular epithelium Primarily necrotic cells Dvergsten et al. (1994); Girton et al. (2001);
Sieber et al. (2009)
Opn Proximal, distal tubular,
and glomerular epithelium
Increased in cytoplasm of intact injured cells Xie et al. (2001a, b)
Kim-1 Proximal tubular epithelium Apical border of intact injured cells; diffuse
cytoplasmic expression in necrotic cells
Zhou et al. (2008); Zhang et al. (2008a);
Sieber et al. (2009)
aGST Proximal tubular epithelium Primarily necrotic cells Feinfeld et al. (1981); Kilty et al. (1998)
mGST Distal tubular epithelium Primarily necrotic cells Feinfeld et al. (1981); Kilty et al. (1998)
Rpa-1 Collecting duct epithelium Increased in cytoplasm of intact injured cells Zhang et al. (2008a); Betton (2008)
Proximal tubular epithelium Primarily necrotic cells
Abbreviations: Alb, urine albumin; Clu, urine clusterin; Kim-1, kidney injury molecule-1; Lcn-2, urine lipocalin-2; Opn, urine osteopontin; Rpa-1, urine renal papillary antigen-1;
Source during injury, cellular source of biomarker; Source phenotype, phenotype of cell during biomarker release; aGst, urine glutathione S-transferase, a; mGst, urine
glutathione S-transferase, Yb1.
Complete reference list for this table is presented in supplementary data as ‘Supplementary Reference List’ online.
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Figure 1 | Experimental timeline. Scale timeline represents the 45-day course of this study, beginning with injection at day 0. I is daily
injection; Sx is the killing number x; No. of daily injections is the number of consecutive daily treatments given before killing; No. of days
post final injection is the number of days between the final injection and killing.
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high-dose group at day 10 (8 days following the final treat-
ment). Medium- and low-dose groups showed a decreasing
trend in all biomarkers at day 10. By day 15, all biomarkers
had resolved to control levels in all dose groups.
Serum biomarker data are presented in Table 3. Blood
urea nitrogen (BUN) and serum creatinine were elevated only
in the high-dose group. BUN was significantly elevated on
days 3 and 7. On days 7 and 10, serum creatinine was
significantly elevated. Trends were not detectable at other
time points or in other dose groups. However, those
elevations that were detected corresponded temporally with
peaks seen in urinary biomarkers (Figure 2).
Table 4 contains two mean values for histopathology score
for every treatment group at each time point. The first value
was obtained through a blinded evaluation (no information
provided other than the agent used) and the second value was
generated 10 months later in an evaluation where treatment
and timing were known. In the blinded evaluation,
significant histopathology differences were shown at day 1
in the high- and medium-dose groups. On days 2, 7, and 10,
there were significant changes in histopathology in all dose
groups relative to control. On day 3, similar changes were
described in all dose groups but significant differences were
not demonstrated. A significant increase in histopathology
Table 2 | Group means for urinary biomarkers at each time point
D n TX Kim-1 Alb Lcn-2 Clu Opn lGst aGst Rpa-1
1 4 0 1.5±0.3 547.4±914.8 382.8±143.2 40.0±11.0 3.4±1.4 14.5±6.5 167.4±93.5 1.69±1.2
4 75 1.9±0.4 431.7±357.9 434.0±129.9 44.7±17.8 5.7±2.5 26.0±8.0 114.4±48.5 1.76±1.1
4 150 4.1±1.8** 206.3±161.3 523.3±180.5 60.0±9.3 5.1±2.2 11.7±8.4 56.0±23.4 0.59±0.5
4 300 6.2±2.1** 3253.0±3822.4 517.2±82.2 68.2±21.8 7.2±1.6 17.5±10.3 62.4± 7.2 0.76±0.5
2 3 0 2.2±1.4 125.5±132.8 558.7±421.8 36.9±11.5 3.5±3.2 0.8±0.8 76.5±33.5 0.9±0.6
4 75 5.5±4.0 1411.6±1939.6 769.9±286.3 103.2±43.9 4.4±2.4 9.4±5.6 108.6±43.4 8.3±6.2
4 150 14.1±12.4 138.9±84.0 1252.4±862.6 235.4±113.8* 6.2±2.1 31.0±1 2.1** 245.3±122.7 4.7±2.2
3 300 12.3±1.4 103.0±68.0 940.9±564.6 155.5±70.8 5.7±2.9 29.6±11.3** 218.9±155.5 9.9±12.0
3 4 0 1.6±0.9 1706.9±2081.3 368.0±202.0 46.4±9.6 3.4±0.9 62.3±32.6 427.6±193.9 3.0±1.8
4 75 4.6±1.5 160.1±210.6 581.4±113.9 73.5±30.1 4.4±2.4 122.6±76.5 3352.9±2360.5 16.1±12.8
4 150 37.5±25.0 319.7±175.6 1270.8±526.2 264.1±37.4 10.2±4.6 35.2±8.8 257.7±64.8 7.9±2.2
4 300 145.0±120.1* 1251.1±1350.5 3089.4±2562.3* 351.8±249.1* 12.2±8.2 100.6±73.5 1868.5±2598.0 13.4±2.3
7 4 0 4.1±3.6 541.1±476.2 702.2±344.8 95.9±57.0 7.3±4.7 32.4±12.1 200.7±94.9 1.5±0.7
4 75 58.7±34.9 384.2±185.8 899.4±314.2 89.1±25.8 10.9±1.9 86.9±25.7 682.9±290.0 15.2±12.3
4 150 149.5±72.0*** 1212.7±556.7 1725.4±739.3 182.4±75.5 15.9±9.7 265.6±119.8 3433.8±2279.0 21.5±6.6
3 300 479.9±129.7*** 57 196.4±80 308.6 5482.1±1601.6*** 2110.3±1578.0** 67.6±35.5** 1682.9±1440.9* 45 329.7±14 275.1*** 105.7±40.9***
10 4 0 1.3±0.5 435.8±777.5 305.6±140.3 38.3±11.9 2.8±1.7 20.2±10.2 143.1±63.9 6.7±7.7
4 75 6.2±4.8 202.4±127.4 532.3±283.1 63.5±14.74 7.6±4.9 60.5±27.1 377.7±144.6 11.9±8.4
4 150 96.5±68.6 381.1±326.9 1117.7±681.5 296.8±290.7 9.4±4.1 88.6±73.7 794.4±727.1 4.5±4.0
4 300 194.0±85.9*** 2234.3±1944.5 2286.4±773.7** 559.9±314.5* 16.9±5.4** 92.0±59.0 893.8±744.3 11.8±9.2
15 4 0 2.6±0.5 1949.5±1364.6 770.2±406.6 143.7±83.4 9.3±5.1 33.8±24.0 224.0±103.8 13.7±17.9
4 75 3.8±1.9 254.0±239.7 435.6±189.7 47.9±20.2 6.9±2.6 45.6±25.2 254.7±224.0 5.8±6.9
4 150 5.3±3.2 283.3±394.7 346.1±46.5 59.2±23.8 7.9±2.2 20.3±6.7 113.0±65.8 2.9±2.7
4 300 3.1±1.4 177.7±163.8 381.4±151.4 44.0±12.5 9.9±7.5 29.7±20.4 190.9±117.9 14.8±13.5
18 4 0 1.0±0.1 192.5±115.7 403.6±61.1 38.8±16.3 3.8±1.6 55.6±57.2 197.0±116.3 1.1±0.4
4 75 1.6±0.4 325.8±251.0 410.2±71.9 87.9±47.9 4.8±1.9 48.8±17.0 327.2±213.2 9.4±4.5*
4 150 3.1±1.5* 103.7±78.1 264.1±103.9 41.0±21.0 8.0±1.7* 23.5±19.7 224.6±191.4 2.2±1.9
4 300 1.9±0.9 171.1±133.0 287.8±96.0 45.6±9.0 5.9±1.8 26.8±15.8 136.6±104.3 6.6±6.5
22 4 0 1.7±0.3 154.3±97.5 325.8±162.7 40.3±12.1 3.4±0.9 36.2±36.8 137.6±42.2 0.0±0.0
4 75 1.5±0.3 179.9±69.6 415.9±89.7 33.7±18.9 4.7±1.3 12.1±7.2 131.2±87.8 0.0±0.0
4 150 1.6±0.3 38.3±46.7 217.0±113.9 55.5±55.0 4.5±1.6 1.0±1.1 0.0±0.0 0.0±0.0
4 300 1.1±0.3 98.0±155.0 169.4±49.8 29.5±13.1 2.6±0.5 0.8±0.7 0.0±0.0 0.0±0.0
29 4 0 1.7±0.4 591.0±755.9 378.5±90.9 78.7±43.2 3.5±0.9 0.9±0.6 0.0±0.0 0.0±0.0
4 75 1.4±0.5 54.8±83.1 232.1±79.3 47.3±29.2 3.5±1.3 1.1±0.4 0.0±0.0 0.0±0.0
4 150 1.4±0.2 3583.5±6928.9 263.9±60.2 40.7±28.0 3.2±1.0 2.2±2.6 9.8±19.7 1.4±2.7
4 300 1.6±0.4 571.3±397.6 283.1±138.0 39.4±26.3 4.6±1.9 1.8±1.5 0.0±0.0 0.0±0.0
36 3 0 1.7±0.4 249.1±382.8 447.3±53.3 39.5±17.8 4.6±1.0 11.7±4.7 83.8±34.0 11.8±8.3
4 75 0.9±0.3 80.3±29.7 256.6±74.9 14.0±3.4 1.8±0.7 12.5±8.4 58.1±53.6 8.0±5.0
4 150 2.0±0.7 693.3±1342.1 256.1±81.9 37.0±5.2 3.0±0.8 28.9±17.4 234.7±181.0 3.0±3.1
4 300 1.0±0.0 120.3±96.1 198.6±104.4 21.4±7.3 3.2±1.8 25.0±11.1 167.2±160.0 3.8±2.4
44 3 0 0.8±0.2 153.9±133.5 173.6±45.8 39.7±8.8 3.0±1.4 12.3±4.0 89.8±44.6 0.6±0.4
4 75 0.8±0.2 221.0±259.3 200.0±69.0 35.4±16.6 1.5±0.5 42.5±63.9 166.7±230.3 2.6±2.0
3 150 0.7±0.4 775.3±99.0 113.9±12.7 45.1±21.9 1.8±0.9 20.6±14.9 82.2±35.3 1.6±0.8
4 300 0.8±0.3 87.1±72.0 112.9±19.9 40.8±18.7 1.6±1.0 17.4±17.6 185.7±276.3 2.4±2.9
Abbreviations: Alb, urine albumin; Clu, urine clusterin; D, days from initial dose; Kim-1, urine kidney injury molecule-1; Lcn-2, urine lipocalin-2; n, rats in group; Opn, urine
osteopontin; Rpa-1, urine renal papillary antigen-1; TX, mg/kg gentamicin; aGst, urine glutathione S-transferase, a; mGst, urine glutathione S-transferase, Yb1.
Alb in mmg/mg urine creatinine (uCr); Kim-1, Lcn-2, Clu, Opn, and both Gsts in ng/mg uCr; and Rpa-1 in Units/mg uCr.
Presented as mean±s.d.
By analysis of variance (post hoc Holms-Sidak) significantly greater than control (TX=0) at *Po0.05; **Po0.01; ***Po0.001.
Raw data (not normalized to uCr) are presented in Supplementary Table S1: Raw data online.
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score persisted in the high-dose group at day 15. However, at
day 18 and beyond, there were no detectable differences
in histopathology between treated and control groups.
The open evaluation closely mirrored the blinded study but
reduced variability and consequently yielded additional
significant elevation for all treatment groups at day 3, for
low- and medium-dose groups at day 15, for medium- and
high-dose groups at day 18, and for the high-dose group
on day 22.
Table 4 also shows mean scores for three pathologic
processes that were scored (necrosis, apoptosis, and regen-
eration). All three processes peak at the same point (day 7);
however, necrosis and apoptosis rose and fell earlier than
regeneration, which increased later but persisted much
longer. Significant increases in apoptosis and necrosis were
detected in the high-dose group at days 1 and 2, and all
gentamicin groups were elevated by day 3, with necrosis and
apoptosis persisting in all groups through days 15 and 10,
0
1e+7
2e+7
3e+7
4e+7
5e+7
6e+7
7e+7
80
60
40
20
0
504020 30100504020 30100
0
20
60
80
100
120
40
504020 30100
504020 30100504020 30100 504020 30100
2000
1500
2500
500
1000
0 0
200
400
600
800
1000
1200
1400
1600
1800
0
50,000
40,000
30,000
20,000
10,000
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
34
32
30
28
26
24
22
20
18
16
14
12
30 504010 20030 504010 20030 504010 200
30 504010 200
5000
6000
4000
3000
2000
1000
0
600
500
400
300
200
100
0
Con
75 mg/kg
150 mg/kg
300 mg/kg
Figure 2 | Similar temporal and dose responses across urinary biomarkers. The x axis¼days in experimental timeline; ____ Con, control
groups;??75mg/kg, 75mg/kg gentamicin dose groups; – – –150mg/kg, 150mg/kg gentamicin dose groups; –?– 300mg/kg, 300mg/kg
gentamicin dose groups. (a) Kim-1 in ng/mg uCr; (b) Alb in mg/mg uCr; (c) Lpn-2 in ng/mg uCr; (d) Clu in ng/mg uCr; (e) Opn in ng/mg uCr;
(f) mGst in ng/mg uCr; (g) aGst in ng/mg uCr; (h) Rpa-1 in Units/mg uCr; (i) BUN in mg/dl serum; (j) sCr in mg/dl serum. Alb, urine albumin;
BUN, blood urea nitrogen; Clu, urine clusterin; Kim-1, urine kidney injury molecule-1; Lcn-2, urine lipocalin-2; Opn, urine osteopontin;
Rpa-1, urine renal papillary antigen-1; uCr, urinary creatinine; aGst, urine glutathione S-transferase, a; mGst, urine glutathione
S-transferase, Yb1.
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respectively. Necrosis and apoptosis elevation continued in
the high-dose group through days 22 and 29, respectively.
Significant regeneration appeared in all gentamicin groups at
day 7 and persisted through day 29, after which all groups
were at control levels. Figure 3 shows histopathology changes
and immunohistochemistry staining for Kim-1 and Rpa-1
seen in the high-dose group over the course of this study.
(Supplementary Figure S2 online demonstrates biomarker
concentration by individual animal.)
Table 5 contains mean kidney expression data in all treat-
ment groups at each time point for the genes (in parenthesis)
responsible for the proteins, Kim-1 (Kim1), Lcn-2Lcn2,
Clu (Clu), and Opn (Spp1). At none of the examined time
points were low-dose group expression changes statistically
significant. At day 3, there are significant expression changes
in both medium- and high-dose groups for all of the genes
evaluated. Expression changes for Kim1 and Spp1 persisted in
both medium- and high-dose groups at day 7. For Lcn2 and
Clu, significant expressions changes at day 7 persisted only in
the high-dose group. At day 10, expression differences were
detectable only in the high-dose group for Kim1, Lcn2, and
Clu. However for Spp1, significant expression increases were
seen in both medium- and high-dose groups. By day 15,
no relevant changes in gene expression were demonstrable.
Table 3 | Group means for serum biomarkers
Day n Dose BUN sCr
1 4 0 19.0±2.4 0.60±0.08
4 75 19.5±1.0 0.35±0.10
4 150 21.5±2.6 0.50±0.08
4 300 23.0±2.4 0.63±0.06
2 3 0 22.8±4.1 0.45±0.10
4 75 23.0±2.2 0.40±0.12
4 150 25.8±5.6 0.53±0.10
3 300 24.5±2.4 0.60±0.14
3 4 0 19.8±4.6 0.45±0.13
4 75 21.8±2.2 0.40±0.12
4 150 22.8±2.2 0.48±0.05
4 300 31.0±4.7*** 0.55±0.13
7 4 0 16.5±3.1 0.45±0.13
4 75 18.0±1.6 0.48±0.10
4 150 22.0±4.5 0.60±0.14
3 300 32.0±4.4*** 1.17±0.31***
10 4 0 15.5±2.6 0.48±0.05
4 75 18.0±1.4 0.35±0.10
4 150 20.3±1.0 0.60±0.08
4 300 17.8±3.0 0.68±0.13*
15 4 0 20.5±3.4 0.25±0.06
4 75 23.0±2.2 0.25±0.06
4 150 22.5±2.5 0.23±0.05
4 300 20.5±2.6 0.28±0.10
18 4 0 22.8±4.2 0.35±0.10
4 75 21.3±5.2 0.23±0.05
4 150 23.8±2.6 0.28±0.10
4 300 21.5±1.7 0.33±0.05
22 4 0 20.5±2.9 0.30±0.11
4 75 22.3±2.1 0.30±0.14
4 150 19.5±2.4 0.35±0.13
4 300 24.0±3.4 0.28±0.10
29 4 0 19.5±2.4 0.55±0.17
4 75 17.0±2.0 0.40±0.08
4 150 15.8±2.1 0.33±0.12
4 300 18.5±3.1 0.45±0.06
36 3 0 14.0±1.0 0.50±0.10
4 75 17.0±1.4* 0.38±0.10
4 150 20.0±1.3* 0.40±0.18
4 300 18.5±2.1** 0.38±0.13
44 3 0 17.3±1.5 0.40±0.10
4 75 20.5±1.0 0.38±0.10
3 150 18.0±5.5 0.40±0.08
4 300 18.5±2.6 0.40±0.18
Abbreviations: BUN, blood urea nitrogen; day, days from initial dose; dose, mg/kg
gentamicin; n, rats in group; sCr, serum creatinine.
BUN and sCr in mg/dl.
Presented as mean±s.d.
By analysis of variance (post hoc Holms-Sidak) significantly greater than control
(dose¼ 0) at *Po0.05; **Po0.01; ***Po0.001.
Table 4 | Group means for histopathology and pathologic
process scores
Histopathology score Pathologic process scores
Day n Dose Blind Open Necrosis Apoptosis Regeneration
1 4 0 0.25 0.25 0.00 0.00 0.00
4 75 0.75 0.75 0.75 0.25 0.00
4 150 1.75* 1.75* 1.00 1.00 0.25
4 300 2.50* 2.25* 1.25* 1.50* 0.25
2 3 0 0.33 0.33 0.00 0.00 0.00
4 75 2.00* 1.75* 0.75 1.00 0.25
4 150 2.00* 2.00* 1.00 1.75 0.75
3 300 2.25* 2.25* 1.30* 2.00* 0.30
3 4 0 1.75 0.75 0.00 0.00 0.00
4 75 2.25 2.25* 1.00* 1.25* 0.50
4 150 3.00 3.00* 2.75* 2.25* 1.50
4 300 2.75 3.25* 3.00* 2.50* 1.00
7 4 0 1.00 1.00 0.00 0.00 0.00
4 75 3.00* 3.00* 1.75* 2.50* 3.00*
4 150 4.50* 4.50* 4.25* 4.25* 4.00*
3 300 5.00* 5.00* 5.00* 5.00* 5.00*
10 4 0 1.00 1.00 0.00 0.00 0.00
4 75 2.25* 2.25* 1.00* 1.00* 2.25*
4 150 4.00* 3.00* 2.50* 2.25* 4.25*
4 300 3.75* 3.75* 3.25* 2.75* 4.50*
15 4 0 1. 50 0.75 0.00 0.00 0.00
4 75 2.00 2.00* 1.00* 1.00 1.50*
4 150 2.25 2.25* 1.25* 0.75 2.25*
4 300 3.00* 2.25* 1.50* 2.00* 2.25*
18 4 0 1.00 0.50 0.00 0.00 0.00
4 75 0.75 0.75 0.25 1.00* 1.25*
4 150 2.00 2.00* 0.75 0.50 1.50*
4 300 2.00 2.00* 1.00* 2.00* 1.75*
22 4 0 1.25 1.00 0.00 0.00 0.00
4 75 0.50 0.50 0.00 0.25 1.25*
4 150 2.00 1.25 0.25 0.50 1.50*
4 300 2.00 2.00* 1.00* 1.50* 1.25*
29 4 0 1.50 1.00 0.00 0.00 0.25
4 75 1.25 0.50 0.00 0.50 1.00*
4 150 1.75 1.00 0.00 0.25 1.00*
4 300 2.00 1.25 0.25 1.25* 1.50*
36 3 0 1.67 1.00 0.00 0.00 0.33
4 75 0.25 0.50 0.00 0.00 1.00
4 150 2.00 0.50 0.00 0.00 1.00
4 300 1.75 1.00 0.25 0.75 1.25
44 3 0 1.33 0.00 0.00 0.00 0.33
4 75 0.75 0.50 0.00 0.00 1.00
3 150 2.00 0.33 0.00 0.00 1.00
4 300 1.50 1.00 0.00 0.75 1.00
Abbreviations: Day, days from initial dose; dose, mg/kg gentamicin; n, rats in group.
Histopathology and pathologic process score 0–5 (see Materials and Methods).
Analysis by t-test or rank-sum test of treated to control (dose¼ 0), significant
at *Pp0.05.
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Gene expression increases varied in magnitude by biomarker.
Increases in expression for Lcn2, Clu, and Spp1 ranged
between 1.5 and 35.0 fold changes. In contrast, significant
increases in Kim1 ranged between 30.0 and 160.0 fold
changes.
Figure 4a shows receiver operator characteristic (ROC)
curves generated from urinary biomarker data across the
entire time course of this study including injury and recovery.
Although Kim-1, Lcn-2, Opn, Clu, and Rpa-1 captured more
area under the curve (AUC) than BUN, only Kim-1 was
statistically significant. Kim-1 outperformed all other urinary
biomarkers except for Opn, which, notably, was the only
urinary biomarker whose relative performance did not
change from injury to recovery. BUN, Kim-1, Lcn-2, Opn,
Clu, and Rpa-1 significantly outperformed serum creatinine.
Figure 4b contains ROC curves generated from urinary
biomarker data only during the initial five time points (days
1, 2, 3, 7, and 10) that included all significant urinary
biomarker elevations during this study. Figure 4c shows ROC
curves generated from data from the final six time points
(days 15, 18, 22, 29, 36, and 44) of the study. All of the
evaluated biomarkers had greater AUC values during these
first five points (injury and first responses) than they did
during the final six time points (repair and recovery
responses) except for Opn, which was essentially unchanged
from injury to recovery. During recovery, there were no
biomarkers superior to BUN, although Kim-1 and Opn had
slightly greater AUC values.
Figures 5 and 6 contain ROC curves based on necrosis
scoring and apoptosis scoring, respectively. These evaluations
using necrosis and apoptosis scores yielded results almost
identical to those using histopathology scores. Figure 7 shows
ROC curves using regeneration scoring to compare biomar-
kers. Rpa-1 outperformed all other biomarkers throughout
the entire time series and particularly during recovery
(AUC¼ 0.87; all others 40.5). During injury, serum creati-
nine and Alb were particularly poor predictors of regeneration.
DISCUSSION
This study was designed to evaluate biomarkers of kidney
injury available on a common, commercially available
platform during gentamicin-induced injury and subsequent
recovery. This study utilized two Meso Scale Discovery
MULTI-SPOT multiplex rat assays, Kidney Injury Panel 1
(Alb, Kim-1, Opn, and Lcn-2) and Argutus AKI Test (Rpa-1,
mGst, and aGst), as well as a single assay for Clu (Meso Scale
Discovery, Gaithersburg, MD). Both multiplex assays and the
single assay met the performance standards described by the
company.
The time course for rise, peak, and fall among the urinary
biomarkers varied slightly, but in each case followed a similar
pattern. Between days 1 and 3, all biomarkers except Alb
demonstrated elevation, followed by a peak at day 7, and
resolution to control levels by day 10 (mGst, aGst, and Rpa-1)
or day 15 (Kim-1, Lcn-2, Clu, and Opn). For all biomarkers
except Alb, there was evidence of a dose response. The
responses of the serum biomarkers, BUN and serum
creatinine, were detectable only in the high-dose group but
followed a similar time course to the urinary biomarkers.
Histopathology confirmed kidney injury and recovery.
Histopathology scores closely reflected the changes seen in
biomarkers measured from days 1 through 10. In all cases,
the increases observed in urinary biomarkers decreased with
resolution of histopathology changes. However, the nature of
the histopathology described differed over the course of this
study. Early changes (days 1 through 10) were degenerative,
apoptotic, and necrotic, whereas later changes were pre-
dominated by regeneration of proximal tubular epithelium.
Histopathology changes observed throughout this study were
consistent with pre-existing literature (Table 1). Open or
blinded evaluation by the pathologist affected significance of
some single data points but did not alter the conclusions
drawn from the data.
The utility of the urinary biomarkers as determined by
ROC analysis varied according to the time course considered.
Using data generated over the entire time course, only Kim-1
outperformed BUN. Over the identical period, BUN, Kim-1,
Opn, Clu, and Rpa-1 were all superior to serum creatinine.
With data only from days 1 through 10 (injury evolution),
both Rpa-1 and Kim-1 were superior to BUN. During this
early time period, Kim-1, Clu, and Rpa-1 outperformed
serum creatinine as markers of histopathology change.
Biomarkers performed with different effectiveness when
evaluated by individual pathological processes (necrosis,
apoptosis, and regeneration). Evaluation by necrosis score or
apoptosis score was generally similar to that seen using
histopathology score. The overall lack of difference was
expected, as necrosis, apoptosis, and histopathology scores
are highly correlated (Pearson’s correlation coefficient of
0.885 and 0.853, respectively). Using regeneration scores,
Rpa-1 outperformed all other biomarkers primarily because
of its strong correlation with regeneration during recovery. If
this finding is consistent across studies, Rpa-1 might serve as
a biomarker for tracking regeneration and kidney repair.
The appearance of urinary Alb is a recognized conse-
quence of glomerular injury and progressive kidney dis-
ease.4,5 Small amounts of Alb are found in the ultrafiltrate of
normal glomeruli. This Alb is re- absorbed via endocytosis in
the proximal tubules.6,7 Therefore, tubular injury is hypothe-
sized to decrease tubular re-absorption and subsequently
increase excretion of Alb, yielding a viable urinary biomarker
of proximal tubular injury. In this study, urinary Alb was
extremely variable, not significantly related to treatment, and
without a detectable trend. The only spike (nonsignificant) in
Alb was noted on day 7 in the high-dose group and correlated
with severe histopathology scores that by definition included
glomerular involvement.
Several roles have been described for Kim-18,9 in proximal
tubular injury. Previously described responses of Kim-110–14
align with the Kim-1 response and sensitivity described in
this study. Kim-1 exhibited the most rapid and largest
response to gentamicin injury and was the superior
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biomarker across the entire time series. Interestingly, Rpa-1
was as good as Kim-1 in predicting histopathology change
during injury evolution. Constitutively, Rpa-1 is found
primarily in collecting ducts of the medulla, but induced
expression in proximal tubules has been demonstrated
following gentamicin-induced necrosis.15 Given the low
constitutive urinary presence, induced excretion from injured
proximal tubular epithelium may make Rpa-1 an early
biomarker of proximal tubular injury and regeneration in
gentamicin-induced tubular injury. Conversely, early eleva-
tion of Rpa-1 might reflect parallel gentamicin-induced
injury and recovery in the collecting ducts. The structure,
function, and gene sequence for Rpa-1 have not been
identified to date, and consequently no human homolog
has been identified. Nevertheless, the FDA biomarker
qualification review team has advised qualification of Rpa-1
as a nonclinical biomarker of acute kidney injury in a narrow
context for drug development.
Lcn-2, Opn, Clu, mGst, and aGst appear in the urine with
kidney injury. Changes in kidney expression of Lcn-2, Opn,
and Clu show that, like Kim-1, they are upregulated with
injury. Lcn-2 has been identified in experimental models with
various nephrotoxins and in clinical patients with acute and
chronic kidney diseases.14,16–19 A role for Lcn-2 in the
development and maturation of epithelial cells has been
suggested,20 and it has been described as a proinflammatory
modulator in several different conditions including renal
injury.21–23 In this study, the performance of Lcn-2 as a
biomarker did not achieve the level seen in a recent study that
also used gentamicin-induced injury.14 In that study, lower
mg/kg doses were administered more frequently (twice daily
versus once daily) over a longer time (7 versus 3 days),
resulting is a larger cumulative dose.
Opn has been identified in multiple organs including
bone, nervous, and kidney tissue. Proposed functions of Opn
include modulation of nitric oxide, calcium regulation,
maintenance of bone and extracellular matrix, and cell
migration/adhesion including chemotaxis of macrophages
and lymphocytes.24 Increased urinary excretion and kidney
gene expression have been documented following injury.25–27
Involvement in the central nervous system has been described
as proinflammatory.28 A role has been suggested for Opn in
kidney repair29 that may or may not be inflammatory. In this
study, Opn was the most persistent biomarker changing
minimally in AUC from injury to recovery. During recovery,
only Opn, Kim-1, and BUN were able to perform beyond the
random 0.5 AUC of a ROC analysis.
Increased urinary excretion and gene expression of Clu
has been associated with kidney injury to both glomeruli and
tubules.10,30,31 However, Clu expression has been described
ubiquitously, including induced expression in the pancreas
during chronic pancreatitis32 and the brain during ischemic
injury.33 The in vivo function of Clu remains ambiguous, but
evidence supports a transport/chaperone role much like a
Figure 3 |Representative photographs demonstrating acute and chronic kidney injury as well as expression of kidney injury
molecule-1 (Kim-1) and renal papillary antigen-1 (RPA-1) in controls and 300mg/kg gentamicin-treated rats. (a–c2) Control rats
exhibited neither epithelial cell injury (a) nor expression of Kim-1 (b) in proximal tubules. Constitutive expression of RPA-1 was present in
the collecting duct (CD) of the papilla (c1) and the cortex (c2). (d–f2) Rats treated with 300mg/kg gentamicin at day 3. Acute tubular
epithelial cell necrosis (d) and Kim-1 expression (e) were detected in some proximal tubules. Expression of RPA-1 was upregulated in the
epithelial cells of significantly dilated CD in the papilla (f1) and the cortex (f2). RPA-1 was also expressed in degenerated epithelial cells of
proximal tubules (f2). (g–i2) Rats treated with 300mg/kg gentamicin at day 7. Severe acute tubular cell necrosis (g) and substantially
increased expression of Kim-1 (h) were seen in epithelial cells of proximal tubules. RPA-1 expression was detected in epithelial cell of CD of
the papilla (i1) and the cortex (i2). RPA-1 was also expressed in necrotic epithelial cells of proximal tubules (i2). (j–l2) Rats treated with
300mg/kg gentamicin at day 15. Acute tubular epithelial cell necrosis (j) was replaced by regeneration of proximal tubular cells. Kim-1
expression (k) was restricted to a few straight proximal tubules. RPA-1 expression was decreased in non-dilated CD of the papilla (l1) and
the cortex (l2); slight expression of RPA-1 remained in a few proximal tubules (l2). (m–p2) Rats treated with 300mg/kg gentamicin at day 36.
Regenerative epithelial cells of proximal tubules were surrounded by fibrous tissues (m). Kim-1 and RPA-1 were occasionally expressed in an
individual proximal tubule (o, p2). Expression of RPA-1 was also decreased in CD of the papilla (p1) and the cortex (p2). Stains: Hematoxylin
and eosin (H&E; a, d, g, j, m), Kim-1 (b, e, h, k, n), and Rpa-1 (c1, c2, f1, f2, i1, i2, l1, l2, o); negative controls described in Supplementary
Figure S3 online; all images at original magnification  200.
Table 5 | Gene expression changes at selected time points
D n TX Kim1 Lcn2 Clu Spp1
3 4 0 1.12±0.59 1.06±0.39 1.02±0.21 1.01±0.16
4 75 12.01±8.81 0.98±0.25 0.66±0.13 0.97±0.22
4 150 136.23±35.24*** 3.41±1.53*** 2.07±0.38*** 3.37±0.27***
4 300 158.46±24.52*** 3.52±0.55*** 1.67±0.24*** 3.73±0.59***
7 4 0 1.08±0.51 1.03±0.29 1.02±0.19 1.07±0.47
4 75 21.74±14.08 2.06±0.60 1.25±0.13 3.30±0.96
4 150 71.84±25.72*** 4.70±1.90 1.46±0.17 8.83±3.32***
3 300 156.47±21.97*** 32.38±24.03** 6.35±2.52*** 25.89±5.32***
10 4 0 1.04±0.36 1.09±0.53 1.00±0.09 1.03±.032
4 75 4.40±3.26 1.97±1.07 1.30±0.11 1.88±0.58
4 150 23.02±9.07 9.50±6.63 1.72±0.26 7.94±2.51***
4 300 33.34±24.37* 14.16±7.97* 2.83±1.06** 12.86±4.94***
15 4 0 1.03±0.31 1.09±0.44 1.02±0.22 1.01±0.19
4 75 2.97±2.26 2.70±1.10 1.10±0.22 1.62±0.54
4 150 4.82±3.00 3.65±1.62 1.05±0.26 2.57±1.05*
4 300 2.29±0.42 2.01±0.43* 1.01±0.19 1.86±0.44
22 4 0 1.02±0.21 1.04±0.28 1.02±0.24 1.01±0.15
4 75 2.39±1.02 1.76±0.66 1.23±0.10 1.40±0.33
4 150 3.15±1.73 2.27±1.02 1.45±0.21* 1.82±0.59
4 300 1.95±0.44 1.39±0.09 1.22±0.07 1.43±0.32
29 4 0 1.24±1.06 1.08±0.54 1.04±0.38 1.09±0.56
4 75 1.67±1.01 1.31±0.49 1.06±0.35 1.12±0.48
4 150 1.36±0.35 1.41±0.18 0.93±0.12 1.28±0.08
4 300 1.36±0.60 0.82±0.14 0.93±0.07 0.84±0.28
Abbreviations: Clu, clusterin gene; D, days from initial dose; Kim1, kidney injury
molecule-1 gene; Lcn2, lipocalin-2 gene; n, rats in each group; Spp1, osteopontin
gene; TX, mg/kg gentamicin.
All values are fold change from control (TX=0).
Presented as mean±s.d.
By analysis of variance (post hoc Holms-Sidak) significantly greater than control at
*Po0.05; **Po0.01; ***Po0.001.
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heat shock protein.10,34 The described participation of Clu in
cell stress modulation, protein repair, and apoptosis decision
making are similar to the functions ascribed to heat shock
proteins. In this study, Clu performed best in the acute injury
phase.
Minimal animal numbers in each group made necessary a
very conservative interpretation of the statistical data from
this study. This lack of power limited some of the conclu-
sions that could be drawn. However, data for the urinary
biomarkers strongly supported one another across both time
Kidney International (2011) 79, 1186–1197 1193
RL Rouse et al.: Urinary biomarkers during kidney injury and recovery o r ig ina l a r t i c l e
Superior
to BUN
Kim-1 BUN, A = 0.72
Superior
to sCr
Superior
to BUN
Equal to
BUN
Equal to
sCr
Alb, Lcn-2, Opn, μGst,
αGst
Rpa-1, A = 0.94 Rpa-1, A = 0.62
αGST, A = 0.74 αGST, A = 0.47
μGST, A = 0.75 μGST, A = 0.49
Clu, A = 0.88 Clu, A = 0.56
Opn, A = 0.78 Opn, A = 0.79
Lcn-2, A = 0.80 Lcn-2, A = 0.54
Alb, A = 0.63 Alb, A = 0.49
Kim-1, A = 0.94 Kim-1, A = 0.78
sCr, A = 0.65 sCr, A = 0.32
BUN, A = 0.74 BUN, A = 0.70
Equal to
sCr
Kim-1, Aib, Lcn-2,
Opn, Clu, μGst, Rpa-1
Kim-1, Opn, Clu
αGst
None
Equal to
BUN
Superior
to sCr
Superior
to BUN
Alb, Lcn-2, Opn, Clu,
μGst, αGst
Kin-1, Rpa
Kim-1, Clu, Rpa-1
sCr, A = 0.56
Kim-1, A = 0.88
Alb, A = 0.61
Lcn-2, A = 0.73
Opn, A = 0.80
Clu, A = 0.75
μGST, A = 0.67
αGST, A = 0.65
Alb, Lcn-2, Opn, Clu
μGst, αGst, Rpa-1
Rpa-1, A = 0.79
BUN, Kim-1, Lcn-2,
Opn, Clu, Rpa-1
Alb, μGst, αGst
Equal to
BUN
Superior
to sCr
Equal to
sCr
Figure 4 |Receiver operator characteristic (ROC) analysis evaluating kidney injury biomarker performance by histopathology score.
Values represent proportion of described area under the curve (AUC) for the respective biomarkers; the greater the AUC the better the
performance of the biomarker. Superior performer in chart indicates significant difference in AUC relative to named serum marker at
Pp0.05. The ROC curves depict the relative performance of the biomarkers: (a) over the time course of the study; for ROC positive¼ 117;
negative¼ 55; (b) over the first five time points of the study that encompass all significant biomarker alterations; for ROC positive¼ 58;
negative¼ 21; (c) over the final six time points of the study that represent recovery; positive¼ 59; negative¼ 24. Alb, urine albumin;
BUN, blood urea nitrogen; Clu, urine clusterin; Kim-1, urine kidney injury molecule-1; Lcn-2, urine lipocalin-2; Opn, urine osteopontin;
Rpa-1, urine renal papillary antigen-1; uCr, urinary creatinine; aGst, urine glutathione S-transferase, a; mGst, urine glutathione
S-transferase, Yb1.
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Figure 5 |Receiver operator characteristic (ROC) analysis evaluating kidney injury biomarker performance by necrosis score. Values
represent proportion of described area under the curve (AUC) for the respective biomarkers; the greater the AUC the better the performance
of the biomarker. The ROC curves depict the relative performance of the biomarkers: (a) over the time course of the study, Kim-1 was
best; for ROC positive¼ 117; negative¼ 55; (b) over the first five time points of the study that encompass all significant biomarker
alterations, Kim-1, Rpa-1, and Clu performed best; for ROC positive¼ 58; negative¼ 21; (c) during the final six time points of the study that
were primarily recovery, Kim-1, Opn, and BUN best reflected necrosis score; positive¼ 59; negative¼ 24. Alb, urine albumin; BUN, blood
urea nitrogen; Clu, urine clusterin; Kim-1, urine kidney injury molecule-1; Lcn-2, urine lipocalin-2; Opn, urine osteopontin; Rpa-1, urine renal
papillary antigen-1; uCr, urinary creatinine; aGst, urine glutathione S-transferase, a; mGst, urine glutathione S-transferase, Yb1.
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Figure 6 |Receiver operator characteristic (ROC) analysis evaluating kidney injury biomarker performance by apoptosis score.
Values represent proportion of described area under the curve (AUC) for the respective biomarkers; the greater the AUC the better the
performance of the biomarker. The ROC curves depict the relative performance of the biomarkers: (a) over the time course of the study,
Kim-1 and Rpa-1 were best; for ROC positive¼ 117; negative¼ 55; (b) over the first five time points of the study that encompass all significant
biomarker alterations, Clu joined Kim-1 and Rpa-1 as a superior performer; for ROC positive¼ 58; negative¼ 21; (c) during the final six time
points of the study that were primarily recovery, there were no standouts; positive¼ 59; negative¼ 24. Alb, urine albumin; BUN, blood urea
nitrogen; Clu, urine clusterin; Kim-1, urine kidney injury molecule-1; Lcn-2, urine lipocalin-2; Opn, urine osteopontin; Rpa-1, urine renal papillary
antigen-1; uCr, urinary creatinine; aGst, urine glutathione S-transferase, a; mGst, urine glutathione S-transferase, Yb1.
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Figure 7 |Receiver operator characteristic (ROC) analysis evaluating kidney injury biomarker performance by regeneration score.
Values represent proportion of described area under the curve (AUC) for the respective biomarkers; the greater the AUC the better the
performance of the biomarker. The ROC curves depict the relative performance of the biomarkers: (a) over the time course of the study,
Rpa-1 was best; for ROC positive¼ 117; negative¼ 55; (b) over the first five time points of the study that encompass all significant
biomarker alterations, all biomarkers were similar except for BUN, sCr, and Alb, which performed more poorly; for ROC positive¼ 58;
negative¼ 21; (c) during the final six time points of the study that were primarily recovery, Rpa-1 best reflected regeneration scores;
positive¼ 59; negative¼ 24. Alb, urine albumin; BUN, blood urea nitrogen; Clu, urine clusterin; Kim-1, urine kidney injury molecule-1;
Lcn-2, urine lipocalin-2; Opn, urine osteopontin; Rpa-1, urine renal papillary antigen-1; uCr, urinary creatinine; aGst, urine glutathione
S-transferase, a; mGst, urine glutathione S-transferase, Yb1.
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and treatment groups. Where available, gene expression data
not only supported the significant urinary protein findings,
but also suggested that with more power other points of
significant difference might be uncovered.
Laboratory rat strains demonstrate age-progressive degen-
erative kidney lesions that must be separated from toxic
injury in histopathology evaluation. Blind histopathology
evaluation required that all lesions be included in the scoring
system. As these degenerative lesions may also cause
biomarker elevation, their inclusion was considered not only
acceptable but desirable. In the open evaluation, these
‘baseline or background’ changes weighed less in the
histopathology evaluation. Inclusion of these lesions in the
blind study elevated histopathology scores in control animals.
Consistent control scores of 1 across the time series in both
evaluations strongly supported a histopathology score p1 as
negative and X2 as positive for ROC analysis.
In this gentamicin-induced model of acute kidney injury
and recovery, Alb was never significant. The remaining serum
and urinary biomarkers with varying degrees of sensitivity
had a similar time course, exhibited a dose response,
corresponded well with histopathology changes, and were
reversible. Based on ROC values, all biomarkers performed
better during injury than during recovery except Opn, which
was consistent across periods. Kim-1 demonstrated the
quickest and largest response to gentamicin-induced injury
and with Rpa-1 and Clu best described evolving histopathol-
ogy. During recovery, Kim-1, Opn, and BUN best reflected
resolving histopathology. Evaluating performance by necrosis
and apoptosis scores did not alter the performance profile of
the biomarkers. However, evaluation by regeneration score
revealed Rpa-1 as the best indicator of tubular regeneration.
MATERIALS AND METHODS
Animal care and treatment
All animal procedures were performed in accordance with the US
Public Health Service Guide for the Care and Use of Laboratory
Animals (IACUC (Institutional Animal Care and Use Committee)
protocol WOAP2006-52) in an AAALAC (Association for Assess-
ment and Accreditation of Laboratory Animal Care)-accredited
facility. Male Sprague-Dawley rats (Harlan, Frederick, MD) were
housed in standard plastic caging and maintained with ad libitum
food and water on a 12 h light/dark cycle at 22–24 1C.
A total of 176 13-week-old rats were weighed (average 394 g) and
randomly divided into four groups that (based on average weight)
received daily intramuscular injections of gentamicin sulfate (Sigma,
St Louis, MO) in saline at 0mg/kg (saline only), 75, 150, or 300mg/kg
in equal 0.4ml injection volumes for 1, 2, or 3 consecutive days,
beginning at day 0. Four animals from each group were killed on
days 1, 2, and 3; 24 h following their first, second, or third injections,
respectively. Subsequent killings of four animals from each group
occurred on days 7, 10, 15, 18, 22, 29, 36, and 44.
At 16 h before killing, rats were placed in metabolic cages on a
refrigerated collection rack (Techniplast, Bugguggiate, Italy) for
urine collection. Rats were anesthetized with isofluorane and killed
by exsanguination. The serum was separated from the collected
blood. The left kidney was immediately removed, sectioned longi-
tudinally, and one half placed in RNAlater (Ambion, Austin, TX)
and the other half placed in embedding rings with Neg-50 medium
(Richard-Allan Scientific, Kalamazoo, MI) for frozen section.
The right kidney was harvested and placed in formalin for
histopathology.
Serum and urine analyses for kidney injury
Serum concentrations of Alb, total protein, alkaline phosphotase,
alanine aminotransferase, amylase, total bilirubin, calcium, phos-
phorus, glucose, sodium, potassium, and globulins, BUN, and
creatinine were determined on a Vetscan Model 200 Blood Analyzer
(Abaxis, Union City, CA). Urine creatinine (uCr) was measured
using Creatinine Detection Kits by Assay Design (Ann Arbor, MI).
Kim-1, Alb, Lcn-2, Clu, Opn, mGst and aGst, and Rpa-1 were
quantified in urine on the MesoScale Discovery electrochemilumi-
nescence platform (Meso Scale Discovery, Gaithersburg, MD).
Kidney mRNA extraction and PCR
One half of each right kidney was preserved in RNALater solution
(Ambion). Samples were homogenized and the lysates were treated
with ProteinaseK (Qiagen, Valencia, CA) followed by centrifugation
and ethanol precipitation. RNA samples eluted from minicolumns
were quantified on a NanoDrop ND-8000 spectrophotometer (Thermo
Fisher Scientific, Pittsburgh, PA), and qualitative analyses were per-
formed on an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA).
Relative RNA quantification was determined using real-time
quantitative reverse transcriptase-PCR. cDNA was generated using
VILO superscript cDNA kits (Invitrogen, Carlsbad, CA). PCR was
performed using ABI Power SYBR Green Master Mix (Applied
Biosystems, Carlsbad, CA) on an ABI Prism 7900HT sequence
detection system. The comparative CT method (DDCT) was used to
calculate the relative level of gene expression for each sample. Four
replicate wells were performed on each sample. Gene expression
data were normalized to the endogenous reference gene for 60 s
ribosomal protein, L7. Forward (For) and reverse (Rev) primer
sequences were:
Kim1: For-50-GTGAGTGGACCAGGCACACA-30, Rev-50-AATCC
CTTGATCCATTGTTTTC-30
Lcn2: For-50-ACAACGTCACTTCCATCCTCG-30, Rev-50-TGATC
CAGTAGCGACAGCCC-30
Clu: For-50-GCTTCATTCCCTCCAGTCCA-30, Rev-50-TGTTCC
AGCAGGGATGAGGT-30
Spp1: For-50-TGAACAGTATCCCGATGCCA-30, Rev-50-CTCTTC
ATGCGGGAGGTGA-30
Kidney for histopathology and immunohistochemistry
One formalin-preserved kidney from each experimental animal was
step sectioned longitudinally through the approximate center of the
kidney. A pathologist blinded to treatment status (control/treatment
groups, rats per group, gentamicin dosage, and time point in dosing
or recovery) used four to six hematoxylin and eosin-stained sections
to evaluate kidney injury employing a semiquantitative scoring scale
of 0–5.15 Necrosis, apoptosis, and regeneration scores were based on
the percentage of tubular epithelial cells showing these processes:
0¼ none; 1¼ scant; 2p25%; 3¼ 25–50%; 4¼ 51–75%; and 5X75%
of tubular cells affected. General histopathology scores were a
composite of degeneration, tubular dilation, protein casts, necrosis,
apoptosis, and regeneration: 0¼ no damage; 1¼ degeneration only;
2p25%; 3¼ 25–50%; 4¼ 51–75%; and 5X75% of tubular cells
affected. Following a 10-month washout, the pathologist used the
same procedures to re-evaluate the same sections with knowledge
of treatment group and time point.
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Mouse anti-rat-Kim-1 ectodomain monoclonal antibody
(MARKE) was kindly received from Dr Vishal and S Vaidya
(Harvard Medical School, Boston, MA). Rpa-1 and apoptosis
kit were purchased from Augutus Medical (Dublin, Iceland) and
Trevigen (Gaithersburg, MD), respectively. Immunostaining for
these kidney injury biomarkers and TdT-mediated dUTP nick end
labeling staining for apoptosis have been previously described.15,35
Statistics
One-way analysis of variance or t-tests were used to compare
treatment groups with time-matched controls. For nonparametric
data, the Mann–Whitney rank-sum test was used. ROC analysis
was employed to compare biomarker performance. All statistical
analyses were conducted in SigmaPlot 11 (Systat Software,
San Jose, CA).
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